source
- Actinogen’s Alzheimer’s drug Xanamem fails pivotal trial, shares plunge over 80%Actinogen Medical, an Australian biotech, reported that its only candidate, Xanamem (emestedastat), did not meet the primary endpoint in a Phase 2b/3 study in patients with mild to moderate Alzheim…
- Drugmakers urged to assess device capabilities and engage regulators early for combo productsAt the AFDO/RAPS Combination Products Summit, a panel of experts advised drugmakers that developing standalone medical devices to be used with their drugs requires careful evaluation of the devices…